Cognition, Microbiome, Nutrition, Sleep, Stress
Conditions
Keywords
sleep, gut health, cognition, stress
Brief summary
This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.
Detailed description
This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected. Interested participants will initially be scheduled to complete a screening telephone call with the researcher. Here, electronic informed consent will first be provided by the participant, by accessing a pre-emailed link to the Qualtrics survey platform, to an account which is hosted by Northumbria University. Once consent is obtained, the participant will confirm that they do not meet any of the study exclusion criteria, and will complete the SDS-CL checklist with the researcher, over the phone. If any clinical thresholds are met, participants will be invited to a separate clinical interview (again via phonecall) with Professor Jason Ellis, employing the International Classification of Sleep Disorders (ICSD-3) criteria, to determine elligibility. If participants progress to enrolment, they will be invited to attend a lab-based training/screening session (protocol day -7) at Northumbria University. Here, hard and wet-signed (by both the participant and the researcher) consent forms will be completed and stored on site. Participants will then be familiarised with the study protocol and procedures. Participants will also be trained on the cognitive tasks. During the following 7 nights (Protocol days -7 to -1), participants will monitor their sleep and complete the daily Sleep Diary each morning. During this week, they will also drop off their pre-dose baseline stool sample at a remote drop-off location at Northumbria University. Seven days following the lab-based screening visit (Supplement day 1, Protocol day 0), participants will attend the laboratory for their acute visit. Here, a pre-dose baseline sample of saliva and a single blood sample will be taken (for Alpha Amylase, Cortisol, Serotonin and Melatonin), and Blood Pressure, Heart Rate, Body Mass Index, and Waist-to-Hip Ratio will be measured. Participants will complete the Intake24 dietary assessment, and gastrointestinal symptoms questionnaires, as well as the Pittsburgh Sleep Quality Index (PSQI), State-Trait Anxiety Inventory (STAI), and Depression, Anxiety and Stress Scale - 21 Items (DASS-21). The cognitive task battery will additionally be completed. After completing these measures, participants will receive instructions on the next phase of the trial. From that night, participants will consume their first dose of the investigational supplement (noting the time in their treatyment diary) 4 hours before their normal bed-time. They will monitor their sleep overnight. The following morning (supplementation day 2, protocol day 1), participants will complete their Sleep Diary. Participants will follow this procedure for the following 27 days. At some point during Protocol (Days 12-18), participants will return to Northumbria University to drop-off their interim stool sample. On Protocol day 28, participants will return to the lab for the chronic testing visit. All of the outcome measures assessed during the acute lab visit (Protocol day 0) will be repeated here. At the end of the session, participants will be debriefed, and their participation payment arranged. At some point during Protocol (Days 27-33) participants will return to Northumbria University to drop-off their chronic stool sample.
Interventions
DIETARY_SUPPLEMENTProprietary 'active' composition 1
A proprietary orally administered dietary supplement consisting of standardized ingredients.
DIETARY_SUPPLEMENTProprietary 'active' composition 2
A proprietary orally administered dietary supplement consisting of standardized ingredients.
DIETARY_SUPPLEMENTInactive control supplement
Flavored vehicle
Sponsors
Northumbria University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants must self-assess themselves as being in good health. * Aged 25 to 60 years at the time of randomisation * Fluent in English * Identify as a 'poor sleeper' as defined subjectively (i.e. poor sleep quality, unrefreshing sleep) and a total score of \>5 on the Pittsburgh Sleep Quality Index (PSQI).
Exclusion criteria
* Member of own household currently participating in this trial * Evidence of current or recent sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders), taking any medication which exerts sedative effects, affects the CNS and/or sleep, or be currently unwell with any illness that affects sleep (i.e. disorders of the CNS). An initial screening for sleep disorders will be conducted using the Sleep Disorders Symptom Checklist-25 (SDS-CL; Klingman et al., 2017). If a participant reports positively to any of the 25 questions in terms of being affected for three nights per week, or more, this will be followed up using a clinical interview according to the International Classification of Sleep Disorders (ICSD-3) to exclude on the basis of a sleep disorder * History of seizures or epilepsy * Shift working or have a history of shift work within the previous six months * Currently, or within the previous 8 weeks, consuming any nutritional supplements. * Participation in any other intervention research trials * Sleeping at a location other than their usual residence more than two nights per week during participation * Travel across multiple time zones within the last three months or have planned travel across multiple time zones during the study * Current or recent mood disturbances or Axis I disorders (descriptions will be given) * Current misuse of alcohol and/or drugs * Current smoker * Recent (within the last 12 weeks) infection and/or use of antibiotic medication * Pregnant, seeking to become pregnant or lactating * Those using (including within the last 2 weeks) proton-pump inhibitors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sleep Efficiency (SE) | Change from Baseline to end of supplementation period at 28 days | Sleep efficiency (SE), commonly defined as the ratio of total sleep time (TST) to time in bed (TIB), will be reported as a percentage of time in bed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Actigraphy - Sleep onset latency | Change from baseline following 28 days of supplement consumption | recorded minutes taken from intention to sleep to sleep initiation |
| Actigraphy - Sleep efficiency | Change from baseline following 28 days of supplement consumption | ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage) |
| Actigraphy - Number of awakenings | Change from baseline following 28 days of supplement consumption | recorded number of awakenings during entire sleep period |
| Actigraphy - Wake after sleep onset (WASO) | Change from baseline following 28 days of supplement consumption | recorded minutes awake during the entire sleep period following sleep onset |
| COMPASS global performance measures | Change from baseline following 28 days of supplement consumption | Speed of performance, and accuracy of performance measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University) |
| Pittsburgh Sleep Quality Index (PSQI) | Change from baseline following 28 days of supplement consumption | Pittsburgh Sleep Quality Index (PSQI): Total Score. The PSQI is a validated self-rating instrument assessing aspects of sleep quality.Minimum score 0 (better); maximum score 21 (worse) \< or = 5 associated with good sleep quality; \> 5 associated with poor sleep quality. |
| Depression, Anxiety and Stress Scale - 21 Items (DASS-21) | Change from baseline following 28 days of supplement consumption | A 21-item measure of mood over the previous week (each item is rated on scale from 0-3). Scoring creates 3 component scores: depression, anxiety and stress (each on a scale of 0-21) with higher scores indicating higher symptomology. Cut-off scores, according to each set of symptoms, are available (normal, mild, moderate, severe and extremely severe) or total scores can be derived by multiplying the sum of all three component scores by 2. |
| State-Trait Anxiety Inventory (STAI) | Change from baseline following 28 days of supplement consumption | A 40-item measure of current and general anxiety levels. Each item is rated on a scale from 1-4. Scoring creates two components: state anxiety (20 items) and trait anxiety (20 items), with a range for each between 20-80. Following transformation through reversed coding, higher scores indicate higher levels of anxiety |
| Actigraphy - Total sleep time | Change from baseline following 28 days of supplement consumption | recorded minutes asleep over entire sleep period |
| Sleep Diary - Total sleep time | Change from baseline following 28 days of supplement consumption | recorded minutes asleep over entire sleep period |
| Sleep Diary - Sleep onset latency | Change from baseline following 28 days of supplement consumption | logged minutes taken from intention to sleep to sleep initiation |
| Sleep Diary - Sleep efficiency | Change from baseline following 28 days of supplement consumption | ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage) |
| Sleep Diary - Number of awakenings | Change from baseline following 28 days of supplement consumption | logged number of awakenings during entire sleep period |
| Sleep Diary - Wake after sleep onset (WASO) | Change from baseline following 28 days of supplement consumption | logged minutes awake during the entire sleep period following sleep onset |
Countries
United Kingdom
Contacts
CONTACTPamela Alfonso-Miller, MD
PRINCIPAL_INVESTIGATORProfessor Jason Ellis, PhD
Northumbria University
Outcome results
None listed